Trial Profile
Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Goserelin; Letrozole; Tamoxifen
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms SUCCESS-B
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003641).
- 02 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 02 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.